BioNexus Gene Lab Corp. (BGLC) Stock Overview
Explore BioNexus Gene Lab Corp.’s financial performance, market position, analyst ratings, and future outlook.
BioNexus Gene Lab Corp. (BGLC)
Key Financials
Key Financials
Market Cap
3.9M
P/E Ratio
-1.25
EPS (TTM)
$-1.49
ROE
-0.33%
BGLC Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of BioNexus Gene Lab Corp. (NASDAQ: BGLC) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of C+, BioNexus Gene Lab Corp.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of BGLC on the NASDAQ shows an RSI of 47.89, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $3.98 for the NASDAQ listing.
Key metrics behind BioNexus Gene Lab Corp.'s NASDAQ-traded stock include a P/E ratio of -1.25 and a market capitalization of 3.9M. Combined with our AI analysis, these give both institutional and retail investors a clear view of BGLC on the NASDAQ.